

# Dinesh Khanna

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7857016/dinesh-khanna-publications-by-citations.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

418  
papers

25,226  
citations

69  
h-index

147  
g-index

446  
ext. papers

31,670  
ext. citations

5.2  
avg. IF

6.89  
L-index

#	Paper	IF	Citations
418	2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2737-47		1636
417	2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 625-39	4.7	1199
416	Definitions and diagnosis of pulmonary hypertension. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, D42-50	15.1	1163
415	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1747-55	2.4	1109
414	2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 1431-46	4.7	1061
413	Systemic sclerosis. <i>Lancet, The</i> , <b>2017</b> , 390, 1685-1699	40	764
412	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 573-86		520
411	American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 404-13	2.4	518
410	2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 1447-61	4.7	507
409	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1327-1339	2.4	497
408	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1400-1412	9.5	488
407	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , <b>2016</b> , 4, 708-719	35.1	487
406	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1340-9	2.4	444
405	Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 323-33		360
404	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (FaSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , <b>2016</b> , 387, 2630-2640	40	359
403	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159	2.4	344
402	Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 176, 1026-34	10.2	343

401	Distinctions between diagnostic and classification criteria?. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 891-7	4.7	268
400	Natural products as a gold mine for arthritis treatment. <i>Current Opinion in Pharmacology</i> , <b>2007</b> , 7, 344-51	5.1	267
399	Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 35-47	59.2	266
398	Methods of formal consensus in classification/diagnostic criteria and guideline development. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 41, 95-105	5.3	204
397	Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , <b>2017</b> , 2, 11-18	2.3	190
396	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 2582-91		182
395	Diagnosis of pulmonary hypertension. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	175
394	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 212-220	2.4	172
393	An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1672-9	4.1	163
392	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 744-760	4.7	157
391	ImmunoChip analysis identifies multiple susceptibility loci for systemic sclerosis. <i>American Journal of Human Genetics</i> , <b>2014</b> , 94, 47-61	11	151
390	Safety of tumour necrosis factor-alpha antagonists. <i>Drug Safety</i> , <b>2004</b> , 27, 307-24	5.1	141
389	Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1257-63		140
388	Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 3194-201		131
387	Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. <i>Ophthalmology</i> , <b>2010</b> , 117, 133-139.e2	7.3	124
386	Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 1804-14	0.7	123
385	Item response theory, computerized adaptive testing, and PROMIS: assessment of physical function. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 153-8	4.1	118
384	Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1612-20	2.4	115

383	Atherosclerosis in systemic sclerosis: a systematic review and meta-analysis. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 2078-90		115
382	Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. <i>Health and Quality of Life Outcomes</i> , <b>2012</b> , 10, 117	3	112
381	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 963-974	35.1	112
380	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 1102-11		108
379	Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 592-600		108
378	A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3540-6		105
377	Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study. <i>Chest</i> , <b>2009</b> , 136, 1333-1340	5.3	104
376	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 832-40	4.1	101
375	Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 489-95	4.7	100
374	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2168-71	4.1	99
373	The future of measuring patient-reported outcomes in rheumatology: Patient-Reported Outcomes Measurement Information System (PROMIS). <i>Arthritis Care and Research</i> , <b>2011</b> , 63 Suppl 11, S486-90	4.7	99
372	Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1903-1913	9.5	92
371	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 666-72	5.3	92
370	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 125-136	9.5	92
369	Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 122-130	2.4	88
368	Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 3016-26	9.5	87
367	Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 2490-8		86
366	Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 3078-85		85

365	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 699-705		85
364	Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 2797-808		83
363	Perceptions of disease and health-related quality of life among patients with gout. <i>Rheumatology</i> , <b>2009</b> , 48, 582-6	3.9	83
362	2020 American College of Rheumatology Guideline for the Management of Gout. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 879-895	9.5	82
361	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , <b>2013</b> , 3,	3	82
360	Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 1676-84		82
359	Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2014</b> , 349, 480-6	4.7	80
358	Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1124-31	2.4	76
357	Gastrointestinal Manifestations of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , <b>2016</b> , 1, 247-256	2.3	75
356	Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials. <i>Thorax</i> , <b>2014</b> , 69, 428-36	7.3	75
355	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2016</b> , 315, 1975-88	27.4	74
354	The minimally important difference for the fatigue visual analog scale in patients with rheumatoid arthritis followed in an academic clinical practice. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 2339-43	4.1	72
353	Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSSciate clinical trial in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1362-1371	2.4	71
352	Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. <i>Rheumatology</i> , <b>2013</b> , 52, 1809-17	3.9	71
351	Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 3821-30		70
350	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 299-311	9.5	69
349	Long-term safety of pegloticase in chronic gout refractory to conventional treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1469-74	2.4	69
348	Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 1451-1460	9.5	67

347	Early detection and management of pulmonary arterial hypertension. <i>European Respiratory Review</i> , <b>2012</b> , 21, 306-12	9.8	67
346	Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1335-42	2.4	67
345	IRF5 polymorphism predicts prognosis in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1197-202	2.4	66
344	Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: short form-36 is responsive to change in chronic gout. <i>Rheumatology</i> , <b>2011</b> , 50, 740-5	3.9	65
343	Validation of potential classification criteria for systemic sclerosis. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 358-67	4.7	64
342	Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 99-105	4.1	62
341	Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. <i>Rheumatology</i> , <b>2011</b> , 50, 330-4	3.9	62
340	Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 372	5.7	61
339	Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1459-64	4.1	61
338	A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 591-7		60
337	Feasibility and construct validity of PROMIS and "legacy" instruments in an academic scleroderma clinic. <i>Value in Health</i> , <b>2012</b> , 15, 128-34	3.3	59
336	Health-related quality of life--an introduction. <i>American Journal of Managed Care</i> , <b>2007</b> , 13 Suppl 9, S218z23		59
335	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , <b>2014</b> , 53, 1172-7	3.9	58
334	Evaluation of an instrument assessing influence of Gout on health-related quality of life. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 2406-14	4.1	58
333	Systemic sclerosis - continuing progress in developing clinical measures of response. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1194-200	4.1	58
332	Timing and magnitude of initial change in disease activity score 28 predicts the likelihood of achieving low disease activity at 1 year in rheumatoid arthritis patients treated with certolizumab pegol: a post-hoc analysis of the RAPID 1 trial. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 1326-33	4.1	57
331	Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 3741-50		57
330	Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 1280-6		57



329	Treatment of acute gout: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 44, 31-8	5.3	56
328	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 44, 55-62	5.3	56
327	Articular involvement in systemic sclerosis. <i>Rheumatology</i> , <b>2012</b> , 51, 1347-56	3.9	56
326	Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans. <i>American Journal of Gastroenterology</i> , <b>2018</b> , 113, 1701-1710	0.7	56
325	Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 374-81	2.4	55
324	Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 455-60	4.1	54
323	Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 996-1002	2.4	54
322	Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosis. <i>Quality of Life Research</i> , <b>2007</b> , 16, 1083-92	3.7	54
321	Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohort. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 440-7		53
320	Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. <i>American Journal of Physiology - Cell Physiology</i> , <b>2014</b> , 307, C2-13	5.4	52
319	Evidence-based management of rapidly progressing systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2010</b> , 24, 387-400	5.3	52
318	Management of connective tissue diseases associated interstitial lung disease: a review of the published literature. <i>Current Opinion in Rheumatology</i> , <b>2016</b> , 28, 236-45	5.3	52
317	Lung Transplant Outcomes in Systemic Sclerosis with Significant Esophageal Dysfunction. A Comprehensive Single-Center Experience. <i>Annals of the American Thoracic Society</i> , <b>2016</b> , 13, 793-802	4.7	52
316	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) definition. <i>Journal of Scleroderma and Related Disorders</i> , <b>2017</b> , 2, 115-120	2.3	49
315	Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1634-1643	9.5	49
314	Outcome measures in systemic sclerosis: an update on instruments and current research. <i>Current Rheumatology Reports</i> , <b>2007</b> , 9, 151-7	4.9	49
313	Management of gastrointestinal involvement in scleroderma. <i>Current Treatment Options in Rheumatology</i> , <b>2015</b> , 1, 82-105	1.3	48
312	Health values of patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 86-93		48

311	Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II. <i>Annals of the American Thoracic Society</i> , <b>2018</b> , 15, 1286-1295	4.7	48
310	Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. <i>Thorax</i> , <b>2014</b> , 69, 123-9	7.3	47
309	Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database. <i>Medicine (United States)</i> , <b>2017</b> , 96, e8980	1.8	47
308	Cytotoxic CD4+ T lymphocytes may induce endothelial cell apoptosis in systemic sclerosis. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 2451-2464	15.9	47
307	Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 644-652	10.2	47
306	Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS). <i>Chest</i> , <b>2018</b> , 154, 862-871	5.3	47
305	Histone Deacetylase 5 Is Overexpressed in Scleroderma Endothelial Cells and Impairs Angiogenesis via Repression of Proangiogenic Factors. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2975-2985	9.5	46
304	Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 1450-7	4.1	45
303	Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 3695-3702	11.5	44
302	Association of tumor necrosis factor alpha polymorphism, but not the shared epitope, with increased radiographic progression in a seropositive rheumatoid arthritis inception cohort. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 1105-16		44
301	Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention. <i>Clinical and Experimental Rheumatology</i> , <b>2011</b> , 29, S22-5	2.2	44
300	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 648-656	2.4	43
299	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2015</b> , 44, 680-6	5.3	43
298	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , <b>2014</b> , 33, 207-14	3.9	43
297	The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 588-91	2.4	43
296	Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 305	5.7	42
295	Prevalence and correlates of sleep disturbance in systemic sclerosis--results from the UCLA scleroderma quality of life study. <i>Rheumatology</i> , <b>2011</b> , 50, 1280-7	3.9	42
294	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 351-7	4.7	41



293	Measuring response in the gastrointestinal tract in systemic sclerosis. <i>Current Opinion in Rheumatology</i> , <b>2013</b> , 25, 700-6	5.3	41
292	Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. <i>Rheumatology</i> , <b>2010</b> , 49, 955-9	3.9	41
291	Interaction between RANKL and HLA-DRB1 genotypes may contribute to younger age at onset of seropositive rheumatoid arthritis in an inception cohort. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 3093-103		41
290	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2020</b> , 201, 650-660	10.2	41
289	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , <b>2014</b> , 67, 706-14	5.7	40
288	Infliximab may be effective in the treatment of steroid-resistant eosinophilic fasciitis: report of three cases. <i>Rheumatology</i> , <b>2010</b> , 49, 1184-8	3.9	40
287	Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. <i>Current Rheumatology Reports</i> , <b>2009</b> , 11, 111-9	4.9	40
286	Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1920-4	4.1	40
285	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 724-726	2.4	38
284	Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1373-1384	4.7	38
283	Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: post-hoc analysis of a randomized controlled trial. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 990-6	4.1	38
282	Gout disease-specific quality of life and the association with gout characteristics. <i>Patient Related Outcome Measures</i> , <b>2010</b> , 2010, 1-8	2.9	38
281	Management of systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , <b>2019</b> , 31, 241-249	5.3	38
280	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSICIS trial. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 96-106	35.1	38
279	Points to consider for skin ulcers in systemic sclerosis. <i>Rheumatology</i> , <b>2017</b> , 56, v67-v71	3.9	37
278	Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1301-1310	9.5	37
277	Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 667-72	4.7	37
276	Old medications and new targeted therapies in systemic sclerosis. <i>Rheumatology</i> , <b>2015</b> , 54, 1944-53	3.9	36

275	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, 493	5.7	36
274	Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. <i>Rheumatology</i> , <b>2009</b> , 48, 1537-40	3.9	36
273	Emerging strategies for treatment of systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , <b>2016</b> , 1, 186-193	2.3	36
272	Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. <i>Chest</i> , <b>2017</b> , 151, 813-820	5.3	35
271	Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 439-444	4.7	35
270	Establishing clinical severity for PROMIS measures in adult patients with rheumatic diseases. <i>Quality of Life Research</i> , <b>2018</b> , 27, 755-764	3.7	35
269	Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease. <i>Rheumatology</i> , <b>2019</b> , 58, 567-579	3.9	35
268	Measuring process of arthritis care: the Arthritis Foundation's quality indicator set for rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 35, 211-37	5.3	35
267	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , <b>2017</b> , 56, 1302-1311	3.9	34
266	Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 1900-8	9.5	34
265	The disutility of chronic gout. <i>Quality of Life Research</i> , <b>2008</b> , 17, 815-22	3.7	34
264	Increased radiographic damage scores at the onset of seropositive rheumatoid arthritis in older patients are associated with osteoarthritis of the hands, but not with more rapid progression of damage. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 2284-92		34
263	Systemic Sclerosis Trial Design Moving Forward. <i>Journal of Scleroderma and Related Disorders</i> , <b>2016</b> , 1, 177-180	2.3	34
262	Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1339-1349	9.5	34
261	Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment. <i>Current Treatment Options in Rheumatology</i> , <b>2016</b> , 2, 252-269	1.3	33
260	GERD symptoms in the general population: prevalence and severity versus care-seeking patients. <i>Digestive Diseases and Sciences</i> , <b>2014</b> , 59, 2488-96	4	33
259	Sensitivity to change of the modified Rodnan skin score in diffuse systemic sclerosis--assessment of individual body sites in two large randomized controlled trials. <i>Rheumatology</i> , <b>2009</b> , 48, 1143-6	3.9	33
258	Validation of single-factor structure and scoring protocol for the Health Assessment Questionnaire-Disability Index. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 53, 536-42		33

257	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 379-386 <sup>2,4</sup>	3.4	33
256	Scleroderma keratinocytes promote fibroblast activation independent of transforming growth factor beta. <i>Rheumatology</i> , <b>2017</b> , 56, 1970-1981	3.9	32
255	Assessment of skin involvement in systemic sclerosis. <i>Rheumatology</i> , <b>2017</b> , 56, v53-v66	3.9	32
254	Imaging as an Outcome Measure in Gout Studies: Report from the OMERACT Gout Working Group. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2460-4	4.1	32
253	Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2356-61	4.1	32
252	Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. <i>Rheumatology</i> , <b>2014</b> , 53, 704-13 <sup>9</sup>	3.9	31
251	Preventing tuberculosis flare in patients with inflammatory rheumatic diseases receiving tumor necrosis factor-alpha inhibitors in India -- An audit report. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1414-20	4.1	30
250	Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Multicenter, Double-Blind, Randomized, Placebo-controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 209-221	10.2	30
249	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 618-625	2.4	30
248	Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. <i>Clinical and Experimental Rheumatology</i> , <b>2010</b> , 28, S55-62	2.2	30
247	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 2059-2067	9.5	29
246	Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1367-71	2.4	29
245	Taking charge of systemic sclerosis: a pilot study to assess the effectiveness of an internet self-management program. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 778-82	4.7	29
244	Interstitial lung disease: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. <i>Annals of the American Thoracic Society</i> , <b>2014</b> , 11 Suppl 3, S169-77	4.7	29
243	Treatment of early diffuse systemic sclerosis skin disease. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 166-71	2.2	29
242	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 721-726	4.1	29
241	Arthritis in systemic sclerosis: systematic review of the literature and suggestions for the performance of future clinical trials in systemic sclerosis arthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2012</b> , 41, 801-14	5.3	28
240	Skin gene expression correlates of severity of interstitial lung disease in systemic sclerosis. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2917-27		28

239	Minimally important differences of the gout impact scale in a randomized controlled trial. <i>Rheumatology</i> , <b>2011</b> , 50, 1331-6	3.9	28
238	Responsiveness to Change and Minimally Important Differences of the Patient-Reported Outcomes Measurement Information System Gastrointestinal Symptoms Scales. <i>Digestive Diseases and Sciences</i> , <b>2017</b> , 62, 1186-1192	4	27
237	Twenty-two points to consider for clinical trials in systemic sclerosis, based on EULAR standards. <i>Rheumatology</i> , <b>2015</b> , 54, 144-51	3.9	27
236	Understanding gastrointestinal distress: a framework for clinical practice. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 380-5	0.7	27
235	Pharmacokinetic optimization of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic sclerosis. <i>Bioorganic and Medicinal Chemistry Letters</i> , <b>2017</b> , 27, 1744-1749	2.9	26
234	Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2020</b> , 5, 61-71	2.3	26
233	Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 630-6	4.7	26
232	Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials. <i>Rheumatology</i> , <b>2011</b> , 50, 335-42	3.9	26
231	Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 1772-8	4.7	26
230	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, S23-9	2.2	26
229	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , <b>2019</b> , 58, 18-26	3.9	26
228	Systemic sclerosis: a systematic review on therapeutic management from 2011 to 2014. <i>Current Opinion in Rheumatology</i> , <b>2015</b> , 27, 241-8	5.3	25
227	A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1600-1607	2.4	25
226	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report. <i>Journal of Scleroderma and Related Disorders</i> , <b>2018</b> , 3, 249-252	2.3	25
225	Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1208-1218	2.4	25
224	Screening High-Resolution Computed Tomography of the Chest to Detect Interstitial Lung Disease in Systemic Sclerosis: A Global Survey of Rheumatologists. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 971-972	9.5	24
223	Impact of the revised haemodynamic definition on the diagnosis of pulmonary hypertension in patients with systemic sclerosis. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	24
222	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. <i>Respiratory Medicine</i> , <b>2017</b> , 122 Suppl 1, S14-S17	4.17	24

221	Adverse events during the Scleroderma Lung Study. <i>American Journal of Medicine</i> , <b>2011</b> , 124, 459-67	2.4	24
220	Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients. <i>Quality of Life Research</i> , <b>2006</b> , 15, 1383-94	3.7	24
219	pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	24
218	Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 1686-92	4.1	24
217	Outcome evaluations in gout. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1381-5	4.1	24
216	Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 1633-40	2.4	23
215	and autoantibodies define scleroderma subtypes and risk in African and European Americans and suggest a role for molecular mimicry. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 552-562	11.5	23
214	A world of hurt: failure to achieve treatment goals in patients with gout requires a paradigm shift. <i>Postgraduate Medicine</i> , <b>2016</b> , 128, 34-40	3.7	22
213	Connective tissue disease-associated interstitial pneumonia and idiopathic interstitial pneumonia: similarity and difference. <i>Seminars in Ultrasound, CT and MRI</i> , <b>2014</b> , 35, 29-38	1.7	22
212	Correlates and responsiveness to change of measures of skin and musculoskeletal disease in early diffuse systemic sclerosis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1731-9	4.7	22
211	A delphi exercise to identify characteristic features of gout - opinions from patients and physicians, the first stage in developing new classification criteria. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 498-505	4.1	22
210	Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique. <i>JAMA Ophthalmology</i> , <b>2009</b> , 127, 1155-60		22
209	5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 4350-4369	8.3	21
208	Scleroderma dermal microvascular endothelial cells exhibit defective response to pro-angiogenic chemokines. <i>Rheumatology</i> , <b>2016</b> , 55, 745-54	3.9	21
207	Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. <i>Current Rheumatology Reviews</i> , <b>2010</b> , 6, 138-144	1.6	21
206	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 964-971	9.5	21
205	Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. <i>Clinical and Experimental Rheumatology</i> , <b>2010</b> , 28, S42-6	2.2	21
204	Interstitial lung disease points to consider for clinical trials in systemic sclerosis. <i>Rheumatology</i> , <b>2017</b> , 56, v27-v32	3.9	20



203	Outcome measures in acute gout: a systematic literature review. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 558-68	4.1	20
202	Screening patients with scleroderma for pulmonary arterial hypertension and implications for other at-risk populations. <i>European Respiratory Review</i> , <b>2013</b> , 22, 515-25	9.8	20
201	Predictors of doctor-rated and patient-rated gout severity: gout impact scales improve assessment. <i>Journal of Evaluation in Clinical Practice</i> , <b>2010</b> , 16, 1244-7	2.5	20
200	Oral cyclophosphamide for active scleroderma lung disease: a decision analysis. <i>Medical Decision Making</i> , <b>2008</b> , 28, 926-37	2.5	20
199	Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies. <i>Vaccine</i> , <b>2021</b> , 39, 6111-6116	4.1	20
198	Muscle involvement in systemic sclerosis: points to consider in clinical trials. <i>Rheumatology</i> , <b>2017</b> , 56, v38-v44	3.9	19
197	Points to consider-Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , <b>2017</b> , 56, v45-v48	3.9	19
196	Activation of the Thromboxane A2 Receptor by 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 3153-3162 <sup>19</sup>	4.3	19
195	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1049-1058	9.5	19
194	Work productivity in scleroderma: analysis from the University of California, Los Angeles scleroderma quality of life study. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 176-83	4.7	19
193	OMERACT endorsement of measures of outcome for studies of acute gout. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 569-73	4.1	19
192	Construct validity of the Patient-Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1725-30	4.7	19
191	Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 1040-2	4.1	19
190	A right ventricular diastolic impairment is common in systemic sclerosis and is associated with other target-organ damage. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 439-45	5.3	18
189	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1242-1248	2.4	18
188	Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1316-1325	4.1	18
187	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , <b>2017</b> , 2, 42-49	2.3	18
186	Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. <i>Patient Preference and Adherence</i> , <b>2015</b> , 9, 971-81	2.4	18



185	Health-related quality of life in adults reporting arthritis: analysis from the National Health Measurement Study. <i>Quality of Life Research</i> , <b>2011</b> , 20, 1131-40	3.7	18
184	Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 1059-1067	5.3	18
183	Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 912-919	9.5	18
182	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 128-132	2.4	17
181	Development of an online library of patient-reported outcome measures in gastroenterology: the GI-PRO database. <i>American Journal of Gastroenterology</i> , <b>2014</b> , 109, 234-48	0.7	17
180	Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1706-11	4.1	17
179	Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , <b>2015</b> , 54, 1369-79	3.9	17
178	Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat. <i>Postgraduate Medicine</i> , <b>2014</b> , 126, 65-75	3.7	17
177	Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis. <i>Clinical Immunology</i> , <b>2011</b> , 141, 293-303	9	17
176	Impact of National Institutes of Health Gastrointestinal PROMIS Measures in Clinical Practice: Results of a Multicenter Controlled Trial. <i>American Journal of Gastroenterology</i> , <b>2016</b> , 111, 1546-1556	0.7	17
175	Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features. <i>RMD Open</i> , <b>2019</b> , 5, e000826	5.9	16
174	Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts. <i>Arthritis Research and Therapy</i> , <b>2014</b> , 16, 411	5.7	16
173	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1333-1339	2.4	16
172	Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 907-13	4.7	16
171	Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 686-693	5.3	16
170	Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II). <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 23	5.7	15
169	Management of systemic sclerosis: the first five years. <i>Current Opinion in Rheumatology</i> , <b>2020</b> , 32, 228-237	3.7	15
168	Using Optimal Test Assembly Methods for Shortening Patient-Reported Outcome Measures: Development and Validation of the Cochin Hand Function Scale-6: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 1704-1713	4.7	15

167	Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations. <i>PLoS ONE</i> , <b>2018</b> , 13, e0189498	3.7	15
166	Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 536-41	5.3	15
165	Characterisation of an epigenetically altered CD4(+) CD28(+) Kir(+) T cell subset in autoimmune rheumatic diseases by multiparameter flow cytometry. <i>Lupus Science and Medicine</i> , <b>2016</b> , 3, e000147	4.6	15
164	THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. <i>Rheumatology</i> , <b>2021</b> ,	3.9	15
163	Evaluation of the Satisfaction with Appearance Scale and Its Short Form in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1624-30	4.1	14
162	Osteopontin Links Myeloid Activation and Disease Progression in Systemic Sclerosis. <i>Cell Reports Medicine</i> , <b>2020</b> , 1, 100140	1.8	14
161	Factors influencing early referral, early diagnosis and management in patients with diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , <b>2018</b> , 57, 813-817	3.9	14
160	Randomized Controlled Trial to Evaluate an Internet-Based Self-Management Program in Systemic Sclerosis. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 435-447	4.7	14
159	Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: utility of the University of California, San Diego, Shortness of Breath Questionnaire. <i>Arthritis Care and Research</i> , <b>2013</b> , 65, 454-63	4.7	14
158	COX-2 controversy: where are we and where do we go from here?. <i>Inflammopharmacology</i> , <b>2005</b> , 13, 395-402	5.1	14
157	Multicenter Qualitative Study Exploring the Patient Experience of Digital Ulcers in Systemic Sclerosis. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 723-733	4.7	14
156	Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 176-183	4.1	14
155	Scleroderma--developing measures of response. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 2477-80	4.1	14
154	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 20	5.7	13
153	Willingness to pay for a cure in patients with chronic gout. <i>Medical Decision Making</i> , <b>2008</b> , 28, 606-13	2.5	13
152	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial.. <i>Lancet Rheumatology, The</i> , <b>2020</b> , 2, e743-e753	14.2	13
151	Fatigue and Its Association With Social Participation, Functioning, and Quality of Life in Systemic Sclerosis. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 415-422	4.7	13
150	Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds. <i>ACS Pharmacology and Translational Science</i> , <b>2019</b> , 2, 92-100	5.9	12

149	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1892-1896	9.5	12
148	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , <b>2020</b> , 5, 61-71	2.3	12
147	Associations between a scleroderma-specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 57-63	2.2	12
146	Systemic sclerosis: commonly asked questions by rheumatologists. <i>Journal of Clinical Rheumatology</i> , <b>2015</b> , 21, 149-55	1.1	11
145	Occupational Therapy Treatment to Improve Upper Extremity Function in Individuals with Early Systemic Sclerosis: A Pilot Study. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1653-1660	4.7	11
144	Functional disability and other health-related quality-of-life domains: points to consider for clinical trials in systemic sclerosis. <i>Rheumatology</i> , <b>2017</b> , 56, v17-v22	3.9	11
143	Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 113, 146-149	2.2	11
142	Points to consider in renal involvement in systemic sclerosis. <i>Rheumatology</i> , <b>2017</b> , 56, v49-v52	3.9	10
141	A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 202	5.7	10
140	Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1350-1359	9.5	10
139	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 167-78	4.7	10
138	An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. <i>Journal of Scleroderma and Related Disorders</i> , <b>2019</b> , 4, 17-27	2.3	10
137	Racial differences in health-related quality of life and functional ability in patients with gout. <i>Rheumatology</i> , <b>2017</b> , 56, 103-112	3.9	10
136	Classifying radiographic progression status in early rheumatoid arthritis patients using propensity scores to adjust for baseline differences. <i>Statistical Methods in Medical Research</i> , <b>2007</b> , 16, 13-29	2.3	10
135	Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment. <i>Current Treatment Options in Rheumatology</i> , <b>2020</b> , 6, 337-353	1.3	10
134	Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1523-1532	9.5	10
133	Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical Practice. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,	9.5	10
132	Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 8	5.7	10

131	Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 316-325	9.5	10
130	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	10
129	Does incorporation of aids and devices make a difference in the score of the health assessment questionnaire-disability index? Analysis from a scleroderma clinical trial. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 466-8	4.1	10
128	Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 362-370	3.5	9
127	Performance of Gout Impact Scale in a longitudinal observational study of patients with gout. <i>Rheumatology</i> , <b>2016</b> , 55, 982-90	3.9	9
126	Equivalent responses to disease-modifying antirheumatic drugs initiated at any time during the first 15 months after symptom onset in patients with seropositive rheumatoid arthritis. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 550-7	4.1	9
125	Validating and assessing the sensitivity of the Health Assessment Questionnaire-Disability Index-derived Short Form-6D in patients with early aggressive rheumatoid arthritis. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1150-7	4.1	9
124	Long-Term Outcomes in Patients With Connective Tissue Disease-Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta-Analyses of Randomized, Controlled Trials and Observational Registries. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 837-847	9.5	9
123	Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 520-529	9.5	9
122	Reliability and Validity of the Tender and Swollen Joint Counts and the Modified Rodnan Skin Score in Early Diffuse Cutaneous Systemic Sclerosis: Analysis from the Prospective Registry of Early Systemic Sclerosis Cohort. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 791-794	4.1	8
121	Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 1654-1660	9.5	8
120	An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results. <i>International Journal of Rheumatology</i> , <b>2010</b> ,	2	8
119	Functional improvement after patients with rheumatoid arthritis start a new disease modifying antirheumatic drug (DMARD) associated with frequent changes in DMARD: the CORRONA database. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1966-71	4.1	8
118	Quality indicator set for systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , <b>2011</b> , 29, S33-9	2.2	8
117	Patient-reported outcome instruments in clinical trials of systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2020</b> , 5, 90-102	2.3	8
116	Treatment for systemic sclerosis-associated interstitial lung disease. <i>Current Opinion in Rheumatology</i> , <b>2021</b> , 33, 240-248	5.3	8
115	Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1453-1460	2.4	8
114	Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. <i>Clinical and Experimental Rheumatology</i> , <b>2011</b> , 29, S15-21	2.2	8

113	Patient experiences of digital ulcer development and evolution in systemic sclerosis. <i>Rheumatology</i> , <b>2020</b> , 59, 2156-2158	3.9	7
112	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , <b>2018</b> , 57, 152-157	3.9	7
111	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 78-84	4.1	7
110	New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 641-650	2.4	7
109	What tests should you use to assess small intestinal bacterial overgrowth in systemic sclerosis?. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, S117-22	2.2	7
108	Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 106, 106-113	2.2	7
107	Insight into the Contrasting Findings of Therapeutic Trials of Digital Ischaemic Manifestations of Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , <b>2019</b> , 5, 85-103	1.3	6
106	Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma. <i>International Journal of Rheumatic Diseases</i> , <b>2019</b> , 22, 1036-1040	2.3	6
105	Screening and Early Detection of Pulmonary Arterial Hypertension in Connective Tissue Diseases. It Is Time to Institute It!. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 1032-3	10.2	6
104	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 891-896	5.3	6
103	Health care utilization in patients with gout: a prospective multicenter cohort study. <i>BMC Musculoskeletal Disorders</i> , <b>2017</b> , 18, 233	2.8	6
102	Points to consider for designing trials in systemic sclerosis patients with arthritic involvement. <i>Rheumatology</i> , <b>2017</b> , 56, v23-v26	3.9	6
101	Tocilizumab Treatment of Patients with Systemic Sclerosis: Clinical Data. <i>Journal of Scleroderma and Related Disorders</i> , <b>2017</b> , 2, S29-S35	2.3	6
100	An association study of disease activity score components and patient satisfaction with overall health for early RA patients on non-biologic DMARD therapy. <i>Rheumatology International</i> , <b>2012</b> , 32, 2725-9	3.6	6
99	Valuation of scleroderma and psoriatic arthritis health states by the general public. <i>Health and Quality of Life Outcomes</i> , <b>2010</b> , 8, 112	3	6
98	Chapter 5 Gastrointestinal Involvement in Systemic Sclerosis. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 8, 51-61	0.3	6
97	Gouty tophi in a pancreatic pseudocyst. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 565-6		6
96	Psychometric validation of the Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU <sup>2</sup> ) patient-reported outcome instrument. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 3	5.7	6



95	Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by NarvBz. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, e124	2.4	6
94	Rituximab for the treatment of systemic sclerosis-interstitial lung disease. <i>Rheumatology</i> , <b>2021</b> , 60, 489-491	3.9	6
93	Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. <i>Genome Medicine</i> , <b>2021</b> , 13, 35	14.4	6
92	Points to consider when doing a trial primarily involving the heart. <i>Rheumatology</i> , <b>2017</b> , 56, v12-v16	3.9	5
91	Points to consider for clinical trials of the gastrointestinal tract in systemic sclerosis. <i>Rheumatology</i> , <b>2017</b> , 56, v4-v11	3.9	5
90	Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open Label Extension of a Phase 3 Randomized Controlled Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> ,	10.2	5
89	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2022</b> , 7, 24-32	2.3	5
88	Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting. <i>Journal of Clinical Rheumatology</i> , <b>2020</b> , 26, 115-118	1.1	5
87	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1005-1013	9.5	5
86	Performance of the DETECT Algorithm for Pulmonary Hypertension Screening in a Systemic Sclerosis Cohort. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1731-1737	9.5	5
85	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: subgroup analyses by autoantibody status and skin score. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,	9.5	5
84	Angiocentric T cell lymphoma of the central nervous system in a patient with Sjögren's syndrome. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 1548-50	4.1	5
83	Pulmonary hypertension related to systemic sclerosis: points to consider for clinical trials. <i>Rheumatology</i> , <b>2017</b> , 56, v33-v37	3.9	4
82	Capillary Proliferation in Systemic-Sclerosis-Related Pulmonary Fibrosis: Association with Pulmonary Hypertension. <i>ACR Open Rheumatology</i> , <b>2019</b> , 1, 26-36	3.5	4
81	Examining radiographic outcomes over time. <i>Rheumatology International</i> , <b>2014</b> , 34, 271-9	3.6	4
80	Cardiac metabolomics and autopsy in a patient with early diffuse systemic sclerosis presenting with dyspnea: a case report. <i>Journal of Medical Case Reports</i> , <b>2015</b> , 9, 136	1.2	4
79	Patterns of radiographic outcomes in early, seropositive rheumatoid arthritis: a baseline analysis. <i>Contemporary Clinical Trials</i> , <b>2011</b> , 32, 160-8	2.3	4
78	Development of Clinical Trial Assessments for the Study of Interstitial Lung Disease in Patients who have Connective Tissue Diseases-Methodological Considerations. <i>Current Rheumatology Reviews</i> , <b>2010</b> , 6, 145-150	1.6	4



77	STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung Disease. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1295-1298	4.1	4
76	Emerging drugs for the treatment of scleroderma: a review of recent phase 2 and 3 trials. <i>Expert Opinion on Emerging Drugs</i> , <b>2020</b> , 25, 455-466	3.7	4
75	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. <i>Expert Opinion on Investigational Drugs</i> , <b>2021</b> , 30, 635-652	5.9	4
74	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 170	5.7	4
73	Fatigue Predicts Future Reduced Social Participation, not Reduced Physical Function or Quality of Life in People with Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , <b>2021</b> , 6, 187-193	2.3	4
72	Lymphocyte subset abnormalities in early diffuse cutaneous systemic sclerosis. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 10	5.7	4
71	Interstitial lung disease in systemic sclerosis quantification of disease classification and progression with high-resolution computed tomography: An observational study.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2021</b> , 6, 154-164	2.3	4
70	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , <b>2017</b> , 20, 99-106	7.4	3
69	Health State Utilities and Disease Duration in Systemic Sclerosis: Is There an Association?. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1832-1837	4.1	3
68	Specificity of Systemic Sclerosis Classification Criteria. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2512	4.1	3
67	Ayurvedic medicine: it is "time" for scientifically sound studies. <i>Seminars in Arthritis and Rheumatism</i> , <b>2005</b> , 34, 703-4	5.3	3
66	Assessing disease activity and outcome in scleroderma <b>2011</b> , 1367-1371		3
65	Collaborative National Quality and Efficacy Registry (CONQUER) for Scleroderma: outcomes from a multicenter US-based systemic sclerosis registry. <i>Clinical Rheumatology</i> , <b>2020</b> , 39, 93-102	3.9	3
64	Expansion of FCGR3A macrophages, FCN1 mo-DC, and plasmacytoid dendritic cells associated with severe skin disease in systemic sclerosis. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,	9.5	3
63	A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis: A Narrative Review. <i>JAMA Dermatology</i> , <b>2021</b> , 157, 851-858	5.1	3
62	A Randomized Controlled Trial of Acupressure for the Treatment of Raynaud's Phenomenon: The difficulty of conducting a trial in Raynaud's phenomenon. <i>Journal of Scleroderma and Related Disorders</i> , <b>2016</b> , 1, 226-233	2.3	3
61	Patient perception of disease burden in diffuse cutaneous systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2020</b> , 5, 66-76	2.3	3
60	How do patients define Raynaud's phenomenon? Differences between primary and secondary disease. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 1611-1616	3.9	3

59	Genome-Wide Reduction in Chromatin Accessibility and Unique Transcription Factor Footprints in Endothelial Cells and Fibroblasts in Scleroderma Skin. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 1501-1513	9.5	3
58	The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 963-967	5.3	2
57	Disease modification and other trials in systemic sclerosis have come a long way, but have to go further. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 955-9	4.7	2
56	A randomized study of scleroderma health state values: a picture is worth a thousand words, and quite a few utiles. [corrected]. <i>Medical Decision Making</i> , <b>2009</b> , 29, 7-14	2.5	2
55	Development and Pilot Testing of MyGoutCare: A Novel Web-Based Platform to Educate Patients With Gout. <i>Journal of Clinical Rheumatology</i> , <b>2020</b> , 26, 320-326	1.1	2
54	Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2020</b> , 5, 167-171	2.3	2
53	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. <i>BMJ Open</i> , <b>2021</b> , 11, e044765	3	2
52	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1698-1717	4.1	2
51	Integrating new therapies for systemic sclerosis-associated lung fibrosis in clinical practice. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 560-562	35.1	2
50	Rehabilitation Interventions in Systemic Sclerosis: A Systematic Review and Future Directions. <i>Arthritis Care and Research</i> , <b>2021</b> ,	4.7	2
49	Rituximab for the treatment of systemic sclerosis: urgent need for an international randomised controlled trial. <i>Lancet Rheumatology</i> , <b>2021</b> , 3, e463-e465	14.2	2
48	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , <b>2021</b> , 6, 66-76	2.3	2
47	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2021</b> , 1	12.3	2
46	Small and Large Intestinal Involvement <b>2012</b> , 485-499		1
45	Treatment of Interstitial Lung Disease <b>2012</b> , 421-427		1
44	Measuring Disease Activity and Outcomes in Clinical trials <b>2012</b> , 661-671		1
43	Health-Related Quality of Life and Outcome Measures in Gout <b>2012</b> , 217-225		1
42	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. <i>Journal of Scleroderma and Related Disorders</i> , 239719832110644 <sup>2,3</sup>		1

41	Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 52, 151926-151926	5.3	1
40	Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 19	5.7	1
39	Genome-wide reduction in chromatin accessibility and unique transcription factor footprints in endothelial cells and fibroblasts in scleroderma skin		1
38	Inhibition of histone readers bromodomain extra-terminal proteins alleviates scleroderma fibrosis		1
37	Identification of Pirin as a Molecular Target of the CCG-1423/CCG- 203971 Series of Anti-Fibrotic and Anti-Metastatic Compounds		1
36	Validity and correlates of the Brief Satisfaction With Appearance Scale for patients with limited and diffuse systemic sclerosis: Analysis from the University of California, Los Angeles Scleroderma Quality of Life Study.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2020</b> , 5, 143-151	2.3	1
35	Intensive and app-delivered occupational therapy to improve upper extremity function in early diffuse cutaneous systemic sclerosis: a pilot two-arm trial. <i>Rheumatology</i> , <b>2021</b> , 60, 5002-5011	3.9	1
34	Factors Influencing Patient Decision-Making Concerning Treatment Escalation in Raynaud's Phenomenon Secondary to Systemic Sclerosis. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1845-1852	4.7	1
33	Rational repurposing of tocilizumab for treatment of lung fibrosis in systemic sclerosis. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e321-e323	14.2	1
32	Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial. <i>BMJ Open</i> , <b>2021</b> , 11, e048541	3	1
31	Development of a Musculoskeletal Ultrasound Protocol to Examine Upper Extremity Rehabilitation Outcomes in Systemic Sclerosis. <i>Journal of Diagnostic Medical Sonography</i> , <b>2021</b> , 37, 13-23	0.4	1
30	Racial Disparities in Systemic Sclerosis: Short- and Long-Term Outcomes Among African American Participants of SLS I and II. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 8-16	3.5	1
29	Does hand involvement in systemic sclerosis limit completion of patient-reported outcome measures?. <i>Clinical Rheumatology</i> , <b>2021</b> , 40, 965-971	3.9	1
28	UCLA Scleroderma Clinical Trials Consortium Gastrointestinal Tract (GIT) 2.0 Reflux Scale Correlates With Impaired Esophageal Scintigraphy Findings in Systemic Sclerosis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1422-1426	4.1	1
27	Clinical and psychosocioeconomic impact of COVID-19 pandemic on patients of the Indian Progressive Systemic Sclerosis Registry (IPSSR). <i>Rheumatology Advances in Practice</i> , <b>2021</b> , 5, rkab027	1.1	1
26	A 54-Year Old Woman with Pain and Stiffness of Hands and Tendon Friction Rubs <b>2011</b> , 267-271		1
25	Reliability, construct validity and responsiveness to change of the PROMIS-29 in systemic sclerosis-associated interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 119, 49-56	2.2	1
24	Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 43-51	2.2	1

23	Management of scleroderma gastrointestinal disease: Lights and shadows.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2022</b> , 7, 85-97	2.3	1
22	The association between hand disease severity and fatigue in individuals with systemic sclerosis: a scoping review. <i>Disability and Rehabilitation</i> , <b>2021</b> , 1-7	2.4	0
21	A Case of Recalcitrant Linear Morphea Responding to Subcutaneous Abatacept. <i>Journal of Scleroderma and Related Disorders</i> , <b>2021</b> , 6, 194-198	2.3	0
20	Functional Characterization of Glycoprotein Nonmetastatic Melanoma Protein B in Scleroderma Fibrosis.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 814533	8.4	0
19	Structural Validity of the Rheumatology Attitudes Index in Systemic Sclerosis: Analysis from the UCLA Scleroderma Quality of Life Study. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 795-798	4.1	
18	Response to Screening for Pulmonary Hypertension in Scleroderma <i>Journal of Scleroderma and Related Disorders</i> , <b>2017</b> , 2, e6-e6	2.3	
17	Il buono, il brutto, il cattivo. <i>Thorax</i> , <b>2014</b> , 69, 871-2	7.3	
16	Outcome measures in gout <b>2013</b> , 108-123		
15	Use of a medication control officer to reduce bias in a clinical trial: lessons learned from the scleroderma lung study. <i>Clinical Trials</i> , <b>2010</b> , 7, 85-9	2.2	
14	Dr. Malaviya, et al reply. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 673-673	4.1	
13	Dr. Malaviya, et al reply. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1543.1-1543	4.1	
12	Diagnosis and management of systemic sclerosis. <i>Indian Journal of Rheumatology</i> , <b>2010</b> , 5, 69-75	0.5	
11	Systemic Sclerosis (Scleroderma) and Raynaud's Phenomenon <b>2009</b> , 77-95		
10	Hospitalisations related to systemic sclerosis and the impact of interstitial lung disease. Analysis of patients hospitalised at the University of Michigan, USA. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 131, 43-51	2.2	
9	Reliability, validity, and responsiveness to change of the Patient-Reported Outcomes Measurement Information System self-efficacy for managing chronic conditions measure in systemic sclerosis.. <i>Journal of Scleroderma and Related Disorders</i> , <b>2022</b> , 7, 110-116	2.3	
8	Interpretation of PFTs and Decline in PFTs. <i>In Clinical Practice</i> , <b>2021</b> , 139-149	0	
7	Clinical Outcome Measures in Raynaud's Phenomenon <b>2015</b> , 279-286		
6	Assessing disease activity and outcome in systemic sclerosis (scleroderma) <b>2015</b> , 1159-1164		

5 Measuring Disease Activity and Outcomes in Clinical Trials **2017**, 637-648

4 Gastrointestinal Involvement in Systemic Sclerosis **2014**, 77-87

3 Response to: 'Riociguat in systemic sclerosis: a potential for disease modification' by Jain and Dhir. *Annals of the Rheumatic Diseases*, **2020**, 2.4

2 Reply. *Arthritis and Rheumatology*, **2019**, 71, 327-328 9.5

1 Biologics in Systemic Sclerosis **2022**, 85-99